Johnson & Johnson Agrees to Settle Five Rispersal Suits

Johnson & Johnson agreed to settle five lawsuits over claims that its antipsychotic drug Risperdal caused increased breast-tissue growth in boys.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.